title: Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment.
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg.
authors.forename: C
authors.initials: C
authors.lastname: Bender
authors.affiliation: Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Dimitrakopoulou-Strauss
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg.
authors.forename: A
authors.initials: A
authors.lastname: Enk
authors.affiliation: Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg jessica.hassel@med.uni-heidelberg.de.
authors.forename: J C
authors.initials: JC
authors.lastname: Hassel
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D000074324:Ipilimumab / Q000009:adverse effects*; D061214:Patient Safety; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab